New Hampshire Clinical Trials Report — April 2026

For New Hampshire residents considering participation in clinical research, April 2026 brings both urgent deadlines and exciting new opportunities. A total of 19 clinical trials are slated to close within the next 90 days, creating a critical window for potential participants. Among these rapidly concluding studies, 2 are actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Patients managing certain health challenges also face impending deadlines to join research. Trials focused on various forms of cancer, trauma, and chronic conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Stage IV lung cancer
• Trauma injury
• Anatomic Stage II breast cancer
• Breast cancer
• Chronic granulomatous disease (CGD)
• Congenital heart disease
• Fracture infection
• Crohn disease
• HER2-negative breast carcinoma
• Hormone receptor-positive breast carcinoma

Individuals interested in these specific areas should act quickly to explore eligibility before these studies conclude their recruitment phases.

Groundbreaking Studies Launch in Alopecia Areata, Vitiligo, and Developmental Disabilities

This month, New Hampshire welcomes 3 new clinical trials, matching the number of new studies that opened in March 2026. These new initiatives offer participants the chance to engage with cutting-edge treatments and innovative behavioral interventions. Notably, two significant Phase 2 drug trials from Eli Lilly and Company are now recruiting, alongside a large-scale behavioral study from Temple University.

• Eli Lilly and Company is sponsoring NCT07533006, a Phase 2 study for adult participants with severe alopecia areata, a condition causing significant hair loss. This trial aims to enroll 60 participants to evaluate the effectiveness and tolerability of a new investigational medicine, LY4005130, compared to a placebo. Researchers will also monitor how the body processes the study drug through blood tests.
• Also from Eli Lilly and Company, NCT07533019 is another Phase 2 study, this time focusing on adult participants with non-segmental vitiligo (NSV). This condition causes patches of skin to lose their pigment. Similar to the alopecia trial, this study will assess the tolerability and potential side effects of LY4005130, administered intravenously, against a placebo. It also plans to enroll 60 participants.
• Temple University is leading NCT07505121, a behavioral clinical trial titled "Comparing the Impact of Peer Support vs. Staff-Delivered Transportation Interventions for Young Adults With Intellectual and Developmental Disabilities." This substantial study, designed for 325 participants, will investigate whether young adults with intellectual and developmental disabilities (YA-IDD) achieve better outcomes when a travel training intervention, Ready to Ride (R2R), is taught by a Peer Supporter who shares similar lived experiences, compared to instruction by staff.

Expanding Research Opportunities Across New Hampshire

The new trials this month target specific conditions, offering hope for individuals seeking advanced care. The conditions addressed by these new studies include:

• Alopecia areata
• Developmental disability
• Intellectual disability, mild to moderate
• Non-segmental vitiligo (NSV)
• Vitiligo

Geographically, new research opportunities are emerging in key areas of the state. Of the 3 new trials, 2 have opened in Portsmouth, and 1 has launched in Durham. This distribution allows for greater accessibility for residents in these regions. Overall, New Hampshire currently has 308 clinical trials actively recruiting across 19 cities and 110 research sites, ensuring a broad reach for participation statewide.

Who Can Participate? Healthy Volunteers and Older Adults

While none of the 3 new trials this month are specifically seeking healthy volunteers, there are still significant opportunities for individuals without a particular medical condition to contribute to research. Across New Hampshire, a total of 28 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical advancements.

Regarding specific demographics, 1 of the new trials this month is open to older adults, ensuring that senior populations have the opportunity to participate in and benefit from new research. No new trials are exclusively for children, females, or males this month.

The research landscape in New Hampshire continues to be shaped by both industry and academic sponsors. Eli Lilly and Company, a major pharmaceutical firm, is driving 2 of the new drug trials, while Temple University is leading the behavioral study. This mix of industry and academic involvement ensures a diverse range of research approaches and therapeutic areas are being explored.

As we move through spring, New Hampshire's clinical research community will continue to focus on advancing medical knowledge, with ongoing enrollment in these new studies and the anticipation of future breakthroughs for a wide range of health conditions.